1 Min Read
BRUSSELS, Nov 8 (Reuters) - Galapagos NV : * Glpg0634 phase 2a multicenter trial shows dose-response, confirms excellent
safety and significant clinical benefit in rheumatoid arthritis patients * Drug would treat rheumatoid arthritis
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.